CNB-001

• UNSPSC Description:

  CNB-001 is a potent 5-lipoxygenase (5-LOX) inhibitor, decreases 5-LOX expression, and increases proteasome activity. CNB-001 also increases eIF2α phosphorylation and HSP90 and ATF4 levels in Alzheimer's disease transgenic mice, and limits the accumulation of soluble Aβ and ubiquitinated aggregated proteins. CNB-001 maintains the expression of synapse-associated proteins and improves memory. CNB-001 can be used for the research of Alzheimer's disease[1].

• Target Antigen:

  Lipoxygenase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/cnb-001.html

• Purity:

  90.70

• Solubility:

  10 mM in DMSO

• Smiles:

  OC1=CC=C(C=C1OC)/C=C/C2=NN(C3=CC=CC=C3)C(/C=C/C4=CC(OC)=C(O)C=C4)=C2

• Molecular Weight:

  440.49

• References & Citations:

  [1]Valera E, et al. Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease. J Neurosci. 2013 Jun 19;33(25):10512-25.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported

• CAS Number:

  1019110-87-2